Please assess the completion status of the following clinical trial:

Trial Title: Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected methicillin-resistant staphyloccocus aureus infective endocarditis on a native valve, prosthetic valve or pacemakers´s electrode or defibrillators with definitive or probable diagnosis by the modified Duke criteria (Li J, et al. Clin Infect Dis. 2000).~* Patients over 18 years.~Exclusion Criteria:~* Patients who did not sign informed consent.~* Patients with active consumption intravenous drug.~* Patients with emergent surgery criteria (\<72 hours).~* Patients or cardiogenic shock.~* Patients with antibiotic active against MRSA over 72 hours or they may need another antibiotic active against MRSA than those in the study.~* Patients with chronic renal failure on hemodialysis who received empirical treatment with vancomycin as a single dose and have a valley ≥ 15 mcg / mL on the third day.~* Patients with MRSA strains resistant to fosfomycin (MIC\> 64 mg / L) (\<10%) or vancomycin (MIC\> 2 mg / L) or with an MIC to vancomycin of 2 mg / L.~* Patients with any formal contraindication to be treated with study drugs~* Patients treated with any investigational drug within 30 days prior to entering the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): IV fosfomycin and imipenem adjusted to renal function
- 2 (Type: ACTIVE_COMPARATOR): IV Vancomycin twice a day with valley leves higher than 15 mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).